Sofinnova Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Sofinnova Investments’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-56,900	Closed	-$10.1M	–	81
2021 Q3	$10.1M	Sell	56,900 -21,638	-28%	-$3.48M	0.6%	37
2021 Q2	$12.7M	Sell	78,538 -59,492	-43%	-$9.55M	0.73%	35
2021 Q1	$23.6M	Buy	+138,030	New	+$27.3M	1.42%	20
2020 Q3	–	Sell	-8,072	Closed	-$922K	–	91
2020 Q2	$922K	Buy	+8,072	New	+$783K	0.06%	72
2020 Q1	–	Sell	-108,383	Closed	-$14M	–	72
2019 Q4	$14M	Buy	108,383 +77,583	+252%	+$7.48M	1.01%	22
2019 Q3	$2.4M	Buy	+30,800	New	+$2.89M	0.22%	56
2018 Q2	–	Sell	-8,688	Closed	-$267K	–	69
2018 Q1	$267K	Buy	+8,688	New	+$241K	0.05%	42

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sofinnova Investments's MRTX Position: Q4 2021 in Review

Sofinnova Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 56,900 shares — an estimated $10.1M sold.

Sofinnova Investments first reported a position in MRTX in Q1 2018 and held it in 7 quarters. The position peaked at $23.6M in Q1 2021. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

Sofinnova Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Sofinnova Investments sold 56,900 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $10.1M.
Sofinnova Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
Sofinnova Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $23.6M in Q1 2021.
260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Sofinnova Investments's 13F filing for Q4 2021, filed 14 Feb 2022.